Paliperidone for treatment of schizophrenia

Abstract

In short-term studies, oral paliperidone is an antipsychotic that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain, and tachycardia all more common with paliperidone than placebo. In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. At doses greater than 3 mg per day, oral paliperidone appears comparable in efficacy to oral olanzapine 10 mg per day. Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound.

Fig. 1.

Paliperidone (any dose) versus placebo. Discontinuation of treatment or leaving the study early for any reason.

Fig. 2.

Paliperidone (any dose) versus olanzapine (10 mg). Discontinuation of treatment or leaving the study early for any reason.